4LBA Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated vs conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC)

Guidelines on the radical management of patients with lung cancer

“…No significant difference in local control and overall survival was reported between the CHARTWEL arm and the conventional fractionation arm 299. [1+] …”

Continuous hyperfractionated accelerated radiotherapy – Escalated dose (CHART-ED): A phase I study

“…However, the results from the CHARTWEL study where the dose was escalated to 60 Gy failed to show improvement in local control feeding through to any overall survival benefits 27 .…”

“…The difference in outcomes reported for CHART and CHARTWEL could be a matter of statistical chance, but factors relating to the overall length of the treatment schedule may also be in play as induction chemotherapy was routinely given prior to radiotherapy in the CHARTWEL study 27 . In addition, subgroup analysis 28 from this study does point toward improved outcomes for the accelerated schedule in populations of patients with the larger tumours where you might expect to see the most benefit.…”